文献速递抗栓抗凝管理药物不良反应与药物警戒

达比加群酯:非瓣膜性房颤治疗综述

Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation.
PubMed 文献 · Drugs · 2017-01-01

达比加群酯在欧盟获批用于非瓣膜性房颤患者卒中及系统性栓塞预防。III期RE-LY试验显示,110mg和150mg每日两次剂量在主要疗效终点不劣于华法林,高剂量组卒中/系统性栓塞风险显著低于华法林且大出血风险无显著组间差异。两剂量均显著降低出血性卒中、颅内出血及危及生命大出血发生率,疗效与耐受性在RELY-ABLE扩展研究中维持长达6.7年。

要点

  • 达比加群酯110mg和150mg每日两次在RE-LY试验中主要疗效终点不劣于华法林。
  • 150mg每日两次剂量卒中/系统性栓塞风险显著低于华法林,大出血风险无显著差异。
  • 两剂量均显著降低出血性卒中、颅内出血及危及生命大出血风险。

核心结论

  • 达比加群酯是预防非瓣膜性房颤患者卒中及系统性栓塞的有效选择。

研究设计与样本

  • III期RE-LY试验比较达比加群酯110mg和150mg每日两次与华法林。
  • RELY-ABLE扩展研究评估长达6.7年的疗效与耐受性。

主要发现

  • 110mg和150mg每日两次剂量主要疗效终点(卒中或系统性栓塞风险)不劣于华法林。
  • 150mg每日两次剂量卒中或系统性栓塞风险显著低于华法林,大出血风险组间无显著差异。
  • 两剂量均显著降低出血性卒中、颅内出血及危及生命大出血发生率。
  • 各患者亚组中有效且总体耐受良好。

关键数值与推荐

  • 欧盟批准达比加群酯用于合并非瓣膜性房颤及一个或多个危险因素患者的卒中及系统性栓塞预防。
  • 达比加群酯为直接凝血酶抑制剂达比加群的前药。
  • 常规抗凝监测非必需。
  • 达比加群酯是当前唯一有特异性逆转剂的非维生素K拮抗剂口服抗凝药。

临床怎么用

  • 用于非瓣膜性房颤合并危险因素患者的卒中及系统性栓塞预防。
  • 无需常规抗凝监测。
  • 特异性逆转剂可用。

局限性

  • 与其他非维生素K拮抗剂口服抗凝药的直接比较尚缺乏。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dabigatran etexilate (Pradaxa®) is approved in the EU for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF) and one or more risk factors. Dabigatran etexilate is a prodrug of dabigatran, a direct inhibitor of thrombin. In patients with NVAF in the phase III RE-LY trial, dabigatran etexilate dosages of 110 and 150 mg twice daily were noninferior to warfarin with regard to the risk of stroke or systemic embolism (primary efficacy endpoint). The higher dosage was associated with a significantly lower risk of stroke or systemic embolism than warfarin, with no significant between-group difference in the risk of major bleeding (primary safety endpoint). Both dosages of dabigatran etexilate were associated with significantly lower rates of haemorrhagic stroke, intracranial bleeding and life-threatening major bleeding than warfarin. Dabigatran etexilate was also effective and generally well tolerated across various patient subgroups. The efficacy and tolerability of dabigatran etexilate was maintained for up to 6.7 years in the RELY-ABLE extension study. Routine anticoagulation monitoring is not required in patients receiving dabigatran etexilate, and it is currently the only non-vitamin K antagonist oral anticoagulant (NOAC) with a specific reversal agent available. Although direct comparisons with other NOACs would be beneficial, dabigatran etexilate is a useful option for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

来源:Drugs,查看原文。版权归原作者所有。

引用

  1. Blair HA, Keating GM. Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation. Drugs. 2017. PMID: 28185082. doi:10.1007/s40265-017-0699-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。